Modular Medical Launches Patient Website for Pivot Tubeless Insulin Patch Pump Following FDA Clearance
核心洞察
Modular Medical (搜索) received FDA 510(k) clearance for its Pivot tubeless insulin patch pump in April 2026, clearing the path for U.S. commercial sales.
The Pivot system is the first removable two-part tubeless patch pump featuring a 3 mL detachable reservoir, disposable battery, and smartphone connectivity for bolus and monitoring.
The device targets the approximately 70% of insulin-dependent adults who remain on multiple daily injections due to complexity, cumbersomeness, and cost barriers.
Modular Medical (搜索), Inc. (NASDAQ:MODD) has launched PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy, following the company's receipt of FDA 510(k) clearance for its Pivot insulin delivery system in April 2026. The San Diego-based medical device company remains on track for a commercial launch in the fall of 2026, with initial customer shipments planned by the end of Q2 2026.
The Pivot system represents a first-in-class removable tubeless patch pump designed specifically for people living with diabetes (搜索) who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems.
Addressing the "Almost-Pumper" Market
Approximately 70% of insulin-dependent adults remain on multiple daily injections (MDI) due to what Modular Medical (搜索) identifies as the "3 Cs": complexity, cumbersomeness, and cost. The Pivot system targets this underserved population — referred to as "almost-pumpers" — which the company estimates represents a $3 billion market opportunity.
Jeb Besser, CEO of Modular Medical (搜索), stated: "FDA clearance for Pivot represents years of focused innovation to deliver a truly differentiated tubeless patch pump. By addressing the key barriers — complexity, bulkiness, and high cost — we believe we are positioned to convert millions still on injections to pump therapy."
Device Design and Features
The Pivot is the first two-part tubeless patch pump featuring a removable 3 mL reservoir, a disposable battery, and smartphone connectivity for bolus and monitoring. The system's design emphasizes true electronic accuracy without tubes or constant wear. Notably, the device is removable for showering, sports, or discretion and includes a quick bolus button that operates without a separate controller. The system does not require battery recharging.
The device's two-part reusable pump architecture is intended to reduce both manufacturing costs and user burden, supporting Modular Medical (搜索)'s mission to make "top quality insulin delivery both affordable and simple to learn."
Manufacturing and Commercial Timeline
Production validation lots are well underway, with initial manufacturing capacity supporting approximately 6,000 users on a scalable low-cost platform designed to enable rapid production ramp-up. The company expects initial patients by June 2026, with full commercial launch in the fall.
Software enhancements — including variable bolus capabilities, improved alarms, and automated insulin delivery (AID) compatibility features — are currently in development. Modular Medical (搜索) is also pursuing CE Mark certification, targeted for Q4 2026 to Q1 2027, which would enable sales in European and other international markets.
Company Background
Modular Medical (搜索) was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer who previously founded Tandem Diabetes (搜索) in 2005 and invented and designed its t:slim insulin pump. The company's stated mission is to improve access to the highest standard of glycemic control for people with diabetes (搜索), taking it beyond "superusers" and providing what it describes as "diabetes care for the rest of us."
The newly launched PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the company's focus on real-world usability, supporting patients in evaluating and adopting pump-based diabetes (搜索) care.